Literature DB >> 21225767

Temporal bone verrucous carcinoma: outcomes and treatment controversy.

Mia E Miller1, Neil Martin, Guy F Juillard, Sunita Bhuta, Akira Ishiyama.   

Abstract

OBJECTIVES: Verrucous carcinoma is a rare tumor that presents in the head and neck with the most common sites in the larynx and oral cavity. Fourteen cases of verrucous carcinoma of the temporal bone have been described in the literature; this study aims to examine treatment outcomes and discuss the controversy surrounding postoperative radiation. STUDY
DESIGN: A literature review along with individual case report in the setting of a tertiary care medical center.
METHODS: Outcomes analysis of all cases of verrucous carcinoma of the temporal bone which are documented in the English literature; presentation of a single patient report including gross, histologic, and radiologic analyses.
RESULTS: The longest recorded survival for verrucous carcinoma of the temporal bone occurs in patients treated with surgery alone. Poorer outcomes for patients treated with adjuvant (chemo)radiation may be due to more advanced stage disease at the time of treatment. Early reports of radiation leading to tumor dedifferentiation or early recurrence are not supported by more recent studies. Whether adjuvant radiation therapy is indicated in verrucous carcinoma of the temporal bone remains a controversial.

Entities:  

Mesh:

Year:  2010        PMID: 21225767     DOI: 10.1002/lary.21633

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  2 in total

1.  A Case of Squamous Cell Carcinoma in the External Auditory Canal Previously Treated for Verrucous Carcinoma.

Authors:  Soo Jung Nam; Chan Joo Yang; Jong Woo Chung
Journal:  J Audiol Otol       Date:  2016-11-30

2.  An individual drug-therapy and genetic testing report of temporal bone verrucous carcinoma.

Authors:  Haolei Tan; Yong Liu; Gangcai Zhu; Leiming Pi; Donghai Huang; Xin Zhang
Journal:  Onco Targets Ther       Date:  2014-09-04       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.